Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond (Podcast Pearls)

Experts, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss their thoughts on what to know about managing toxicities associated with FGFR inhibitors in the treatment of urothelial cancer and other malignancies.
Alison Birtle, MD, FRCP, FRCR
person default
Ignacio Duran, MD, PhD
Format: Adobe Acrobat (.pdf)
File Size: 124 KB
Released: May 4, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Janssen Pharmaceutica NV

Related Content

In this downloadable slideset from Clinical Care Options (CCO) Nadia Harbeck, MD, PhD examines the evidence on checkpoint inhibitor therapy in TNBC.

person default Nadia Harbeck, MD, PhD Released: May 11, 2021

In this downloadable slideset from Clinical Care Options (CCO) Ian Krop, MD, PhD explores the evolving role of antibody-drug conjugates in TNBC.

Ian E. Krop, MD, PhD Released: May 11, 2021

Comentario clínico en español sobre la reclasificación molecular de los cánceres de endometrio y ensayos clave de inmunoterapia en curso, de Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: May 10, 2021

Downloadable slides highlighting strategies for assessing and using biomarkers to guide treatment for patients with NSCLC, by Clinical Care Options.

Matthew Gubens, MD, MS Lauren L. Ritterhouse, MD Released: May 7, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue